Data MATRIX Introduces an AI-Operated Patient Survival Assessment Tool

Data MATRIXData MATRIX, a sole Real-World Evidence solutions provider in Russia, has presented a predictive analytics tool for estimating patient survival based on Real-World Data.

An important feature of the presented tool for predictive analysis of Real-World Data is its countrywide potential, and the ability to collect and analyze data on different patient cohorts. That in turn allows the estimation of the survival of a patient based on their individual parameters and performed or planned treatment, before being compared with the best treatment option for similar baseline data. Machine algorithms collect information about patients from medical records received from prevention and treatment facilities, pharmaceutical companies, and researchers in 29 regions of the Russian Federation.

The tool demonstration took place at Skolkovo Innovation Center with the participation of the Russian Ministry of Health, and the Russian Ministry of Economic Development. The event was also attended by representatives of major international and Russian pharmaceutical manufacturers such as Novartis, Janssen, and R-Pharm.

The company's medical director, Polina Shpigotskaya, held a live demonstration of the tool's capabilities to the participants, using breast cancer patients as an example. However, the product is also suitable for other therapeutic areas. In real time, the system processed the information about cancer patients with specified parameters, such as sex, age, degree of malignancy, and menopause status, and displayed in graphs and excel tables the prognosis of survival with the best treatment option for the cohort. The company plans to expand the functionality of the platform, increase the database through partnerships with medical institutions, and scale up the system throughout the Russian Federation.

The event was preceded by Russian President’s Vladimir Putin signing Federal Law which established a regulatory sandbox for 7 digitally innovative projects. Data MATRIX was among the 7 projects that can operate within this legal regime. Under the law, Data MATRIX can process personal data derived from electronic healthcare records (EHRs) in an anonymized form. The company will be able to conduct retrospective clinical studies without signing informed consent and obtain anonymized data from healthcare facilities and data integrators.

As a result, pharmaceutical and biotech companies will have a legally compliant provider of Real-world data (RWD) derived from millions of EHRs. This will contribute to the overall knowledge base on drugs efficacy and safety, including those of vaccines.

For further information, please visit:
https://dm-matrix.com

About Data MATRIX

Data MATRIX RWE offers a wide range of Real World Evidence (RWE) solutions with access to millions of electronic health records. This start-up also delivers clinical data management and biostatistics services and develops software for clinical research. To date, the DM RWE portfolio includes over 200 projects for pharmaceutical and biotechnology companies and CROs. DM RWE products include applications such as EDC, IWRS and ePRO. The company is a member of CDISC, ACDM, SCDM and other professional communities.

Most Popular Now

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...

AI Model Forecasts Disease Risk Decades …

Imagine a future where your medical history could help predict what health conditions you might face in the next two decades. Researchers have developed a generative AI model that uses...

AI Model Indicates Four out of Ten Breas…

A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyses previously unutilised information...

AI Tools Help Predict Severe Asthma Risk…

Mayo Clinic researchers have developed artificial intelligence (AI) tools that help identify which children with asthma face the highest risk of serious asthma exacerbation and acute respiratory infections. The study...

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...